Codexis to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 23
February 09 2023 - 4:05PM
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company,
today announced that it will report its financial results for the
fourth quarter and fiscal year 2022 on Thursday, February 23, 2023,
following the close of market. Codexis management will host a
conference call and webcast at 4:30 p.m. Eastern Time to discuss
the Company’s financial results and provide a business update.
Participants may access the live webcast on the Codexis Investor
Relations website, where it will be archived for 90 days. The live
call can be accessed by dialing (877) 705-2976 (domestic) or (201)
689-8798 (international), conference
ID #13735352. A replay of the call will be
available for 48 hours by dialing (877) 660-6853 (domestic) or
(201) 612-7415 (international), access ID #13726635.
About Codexis
Codexis is a leading enzyme engineering company leveraging its
proprietary CodeEvolver® platform to discover and develop
novel, high performance enzymes and biotherapeutics. Codexis
enzymes have applications in the sustainable manufacturing of small
molecule pharmaceuticals, in RNA and DNA synthesis and the creation
of next generation life science tools, and as gene therapies and
oral enzyme therapies. Codexis’ unique enzymes can drive
improvements such as higher yields, reduced energy usage and waste
generation, improved return on capital in manufacturing, improved
sensitivity in genomic and diagnostic applications, and more
efficacious therapeutics. For more information,
visit www.codexis.com.
Investor Relations Contact:
Argot PartnersBrendan Strong/Carrie McKim(212)
600-1902Codexis@argotpartners.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jul 2023 to Jul 2024